Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jfm1330on Mar 28, 2022 6:52pm
87 Views
Post# 34553724

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Delay in Phase 1 a --------Get over it

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Delay in Phase 1 a --------Get over itThe Gallium 68 imaging part should be in their short term plan if they think they have proof of concept. Toxicity is not a potential problem with Ga68, they should absolutely pursue it with animal model asap just to validate or not this path. The therapeutic side is more complicated because potential toxicity is a real issue, and it would be a long term endeavour to develop that, but doing the imagery part in animal models would already give them more insight into the therapeutic possibilities and about the behaviours of their peptide, organ and tissue distribution, internalization speed into cells, concentration into cells, etc...

As for me knowing more than Christian about PRRT, I will leave it at that. Thera likes to communicate with coded incomplete messages. I will do the same on this one.

SPCEO1 wrote: Guarantee is a strong word so it sounds like you know of what you speak. I guess there is good news and bad news in that. Good news that there is still a chance to do that analysis and bad news that it has not yet be done. 

<br /> <br />
jfm1330 wrote: I can guarantee you that he is not...<br /> <br /> <br /> <blockquote class="BBQuote"> <div> <cite>SPCEO1 wrote:</cite> I am pretty sure Christian is on top of such things way more than any of us, even JFM.</div> </blockquote> <br /> <br />
<br /> <br />


<< Previous
Bullboard Posts
Next >>